Antiplatelets

Antiplatelets

Antiplatelets are a class of medications that prevent blood clots by interfering with platelet aggregation, which is the process by which platelets stick together to form a clot. They play a crucial role in the management of cardiovascular diseases, especially in patients with a history of myocardial infarction or stroke.

Primary Subclasses of Antiplatelets

  1. Aspirin:

    • Mechanism: Aspirin is the most common antiplatelet drug. It works by irreversibly inhibiting cyclooxygenase-1 (COX-1), an enzyme crucial for the production of thromboxane A2, a molecule that promotes platelet aggregation. By blocking this enzyme, aspirin reduces the formation of clots.

    • Usage: It is often used for primary and secondary prevention of cardiovascular events and is typically recommended for patients at moderate to high risk of heart attack or stroke.

  2. Adenosine diphosphate (ADP) receptor blockers:

    • Mechanism: These drugs block the ADP receptor on platelets, specifically the P2Y12 receptor, which prevents ADP from activating platelets and promoting aggregation.

    • Examples: Common ADP receptor blockers include clopidogrel, ticagrelor, and prasugrel. Each has different pharmacokinetics and indications, with clopidogrel often used in combination with aspirin after stent placement.

  3. Glycoprotein IIb/IIIa receptor blockers:

    • Mechanism: These agents block the glycoprotein IIb/IIIa receptor on platelets, preventing them from binding to fibrinogen and other proteins essential for clot formation.

    • Examples: Drugs in this class include abciximab, eptifibatide, and tirofiban, which are often used in acute coronary syndromes and during percutaneous coronary interventions to limit thrombus formation.

  4. Phosphodiesterase (PDE) inhibitors:

    • Mechanism: These medications inhibit phosphodiesterase (PDE), an enzyme that breaks down cyclic adenosine monophosphate (cAMP). Elevated cAMP levels within platelets inhibit platelet activation and aggregation, thus reducing the risk of clot formation.

    • Examples: Cilostazol and dipyridamole are commonly used PDE inhibitors that can be used for intermittent claudication or in specific cases of stroke prevention.